Injectafer Side Effects Linked To Risk of Severe Hypophosphatemia (HPP): Study

Irvin Jackson

Add Your Comments

New research suggests that side effects of Injectafer, an IV medication used to treat iron deficiency, could cause severely low phosphorus levels known as hypophosphatemia (HPP), which can be life-threatening.

In findings published in the August issue of the medical journal Alimentary Pharmacology & Therapeutics, researchers from Norway indicate that Injectafer use was linked to a higher rate of HPP than other treatments for low iron, known as Monofer.

Injectafer (ferric carboxymaltose) was approved for intravenous use by the FDA in 2013. It is an iron replacement by Daiichi Sankyo, meant to treat iron deficiency anemia in adult patients with an intolerance to oral iron supplementation and who have non-dialysis dependent chronic kidney disease.

Do You Know about…

Spinal Cord Stimulator lawsuits

Spinal cord stimulator lawsuits are being investigated for individuals who suffered unnecessary shocks, burns or other problems, often resulting in the need for additional surgery to remove the SCS.

Learn More
SEE IF YOU QUALIFY FOR COMPENSATION
Spinal-Cord-Stimulation-Lawsuit
Spinal-Cord-Stimulation-Lawsuit

Do You Know About…

Spinal Cord Stimulator lawsuits

Spinal cord stimulator lawsuits are being investigated for individuals who suffered unnecessary shocks, burns or other problems, often resulting in the need for additional surgery to remove the SCS.

Learn More
SEE IF YOU QUALIFY FOR COMPENSATION

Researchers in this latest study conducted an observational study of 130 patients with inflammatory bowel disease (IBD) treated with Injectafer or Monofer. Iron deficiency and anemia are common complications linked to IBD.

According to the findings, IDB patients given Injectafer showed a significantly higher risk of moderate-to-severe HPP by week two of treatment. The risks continued to increase through weeks six.

At week 2, the incidence of HPP in Injectafer patients was 56.9%, compared to just 5.7% for patients given Monofer. At six weeks, the incidence rate was 13.7% compared to 1.9%, respectively.

Hypophosphatemia can lead to severe health complications, including:

  • Cardiac arrest
  • Respiratory failure
  • Seizures
  • Muscle weakness
  • Coma
  • Death

“In IBD patients with iron deficiency/iron deficiency anaemia, ferric carboxymaltose was associated with higher incidence, severity and persistence of hypophosphatemia compared with iron isomaltoside,” the researchers concluded. “The presence of moderate-to-severe hypophosphatemia beyond 6 weeks is a clinical concern that requires further investigation.”

A number of lawyers are now evaluating the potential for Injectafer lawsuits against the manufacturer, alleging that patients and the medical community were not adequately warned about the HPP risk and other side effects.

Written by: Irvin Jackson

Senior Legal Journalist & Contributing Editor

Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends.

Tags: Anemia, Daiichi Sankyo, Inflammatory Bowel Disease (IBD), Injectafer, intravenous, Monofer

More Lawsuit Stories

0 Comments

This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

Medtronic SCS Lawsuit Alleges Intellis LT Neurostimulator Caused Worsening Pain
An Illinois woman has joined a growing number of plaintiffs alleging that the Medtronic Intellis neurostimulator, and similar devices, may fail to relieve chronic pain and instead lead to worsening complications.
Court Outlines Plan To Prepare Suboxone Tooth Decay Lawsuits for Trial in Early 2028
Four Suboxone tooth decay lawsuits will eventually be selected and prepared for bellwether trials set to begin in March 2028, according to a court order.
Hair Relaxer Class Action Lawsuit Certification Sought For Medical Monitoring Claims
A federal judge is being asked to certify seven hair relaxer class action lawsuits seeking medical monitoring for users, following studies that link the products to an increased risk of cancer.